Xponance Inc. lowered its holdings in shares of Encompass Health Co. (NYSE:EHC – Free Report) by 14.1% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 10,759 shares of the company’s stock after selling 1,761 shares during the period. Xponance Inc.’s holdings in Encompass Health were worth $923,000 as of its most recent filing with the SEC.
Other institutional investors have also recently bought and sold shares of the company. Trillium Asset Management LLC bought a new stake in Encompass Health in the 1st quarter valued at $4,432,000. TD Asset Management Inc increased its holdings in shares of Encompass Health by 16.0% in the first quarter. TD Asset Management Inc now owns 2,283,674 shares of the company’s stock valued at $188,586,000 after purchasing an additional 314,488 shares during the last quarter. Harbor Capital Advisors Inc. raised its position in shares of Encompass Health by 275.7% in the second quarter. Harbor Capital Advisors Inc. now owns 35,799 shares of the company’s stock valued at $3,071,000 after purchasing an additional 26,270 shares during the period. Epoch Investment Partners Inc. lifted its stake in shares of Encompass Health by 102.9% during the 4th quarter. Epoch Investment Partners Inc. now owns 1,399,341 shares of the company’s stock worth $93,364,000 after buying an additional 709,593 shares during the last quarter. Finally, QRG Capital Management Inc. grew its stake in Encompass Health by 85.6% in the 2nd quarter. QRG Capital Management Inc. now owns 14,365 shares of the company’s stock valued at $1,232,000 after buying an additional 6,627 shares during the last quarter. Institutional investors and hedge funds own 97.25% of the company’s stock.
Insider Activity at Encompass Health
In other news, CFO Douglas E. Coltharp sold 12,260 shares of the stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $86.34, for a total value of $1,058,528.40. Following the completion of the transaction, the chief financial officer now owns 136,227 shares of the company’s stock, valued at $11,761,839.18. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 2.10% of the stock is currently owned by insiders.
Encompass Health Trading Down 1.2 %
Encompass Health (NYSE:EHC – Get Free Report) last announced its quarterly earnings data on Monday, August 5th. The company reported $1.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.01 by $0.10. Encompass Health had a net margin of 7.88% and a return on equity of 17.83%. The business had revenue of $1.30 billion for the quarter, compared to analysts’ expectations of $1.30 billion. During the same period last year, the firm posted $0.95 earnings per share. The firm’s quarterly revenue was up 9.6% compared to the same quarter last year. On average, analysts forecast that Encompass Health Co. will post 4.18 earnings per share for the current fiscal year.
Encompass Health declared that its Board of Directors has approved a stock buyback plan on Wednesday, July 24th that authorizes the company to repurchase $500.00 million in shares. This repurchase authorization authorizes the company to buy up to 5.4% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s board of directors believes its shares are undervalued.
Encompass Health Increases Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 15th. Investors of record on Tuesday, October 1st will be given a dividend of $0.17 per share. This is an increase from Encompass Health’s previous quarterly dividend of $0.15. This represents a $0.68 annualized dividend and a dividend yield of 0.71%. The ex-dividend date of this dividend is Tuesday, October 1st. Encompass Health’s dividend payout ratio is currently 18.38%.
Analyst Ratings Changes
Several equities research analysts have issued reports on EHC shares. Royal Bank of Canada raised their price objective on shares of Encompass Health from $95.00 to $105.00 and gave the stock an “outperform” rating in a research report on Thursday. UBS Group boosted their price target on Encompass Health from $100.00 to $110.00 and gave the company a “buy” rating in a research note on Wednesday. Barclays lowered their price objective on Encompass Health from $113.00 to $109.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 6th. Leerink Partners began coverage on shares of Encompass Health in a research note on Wednesday, July 10th. They issued an “outperform” rating and a $100.00 price target on the stock. Finally, Stephens reaffirmed an “overweight” rating and set a $105.00 price target on shares of Encompass Health in a research report on Tuesday, August 6th. Nine research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, Encompass Health currently has an average rating of “Buy” and an average target price of $102.88.
View Our Latest Analysis on Encompass Health
About Encompass Health
Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.
See Also
- Five stocks we like better than Encompass Health
- Compound Interest and Why It Matters When Investing
- CarMax’s Impressive Rally: What Investors Should Watch Next
- The Role Economic Reports Play in a Successful Investment Strategy
- MarketBeat Week in Review – 9/23 – 9/27
- Learn Technical Analysis Skills to Master the Stock Market
- Wake Up to This Biotech Stock That Still Has Big Potential Upside
Want to see what other hedge funds are holding EHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Encompass Health Co. (NYSE:EHC – Free Report).
Receive News & Ratings for Encompass Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Encompass Health and related companies with MarketBeat.com's FREE daily email newsletter.